Surgery Partners (SGRY) has drawn fresh attention after recent trading left the share price at $13.41. Investors are weighing this move against weak longer term returns and the company’s latest financial profile.
The recent 1-day share price gain of 0.60% offers only a brief pause in a tougher stretch for Surgery Partners, with the 7-day and 30-day share price returns down 6.94% and 5.96% and the 1-year total shareholder return declining 34.23%. This points to fading momentum as investors reassess both growth prospects and risk levels around the current US$13.41 price point.
Scan how Surgery Partners compares with a hand picked group of healthcare peers on our 33 healthcare AI stocks.
Surgery Partners now trades well below both analyst targets and one estimate of intrinsic value, creating a wide valuation gap. Does that discount reflect real business risk, or has the recent slide moved beyond fair value?
Most Popular Narrative: 25% Undervalued
The most followed valuation narrative puts fair value for Surgery Partners at $17.95, which sits well above the recent $13.41 close and frames the current discount as a bet on execution improving from here.
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution.
Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance. The tone is mixed, with some analysts still highlighting long term growth levers while others are focused on execution risks tied to margins, payer mix, and deal flow.
See why 5 investors see Surgery Partners as 25% undervalued.
Result: Fair Value of $17.95 (UNDERVALUED)
Still, higher interest costs on floating debt and slower than planned acquisitions could pressure Surgery Partners’ earnings story and challenge the current undervalued narrative.
Find out about the key risks to this Surgery Partners narrative.
Next Steps
If the tone so far feels cautious, that is exactly why checking the underlying numbers yourself matters and doing it soon keeps your view current. To see what investors see as the main bright spots, review the 3 key rewards.
Looking for more investment ideas beyond Surgery Partners?
You have seen how investors are debating Surgery Partners. Now is the time to widen your watchlist and line up a few fresh ideas.
- Target resilient opportunities that aim to balance potential upside with measured risk by reviewing the 31 resilient stocks with low risk scores.
- Spot potentially mispriced opportunities before the crowd catches on by scanning the 19 high quality undiscovered gems.
- Strengthen your core holdings with financially robust businesses by using the list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com